Intended for healthcare professionals


Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective

BMJ 2017; 356 doi: (Published 08 March 2017) Cite this as: BMJ 2017;356:j1228

The competing interest statement in this article by Neil Lineberry and colleagues was incomplete (BMJ 2016;355:i5078, doi:10.1136/bmj.i5078). As well as the reported links with MPIP, BM is a shareholder at …

View Full Text